Becton Dickinson
BDX
$192.00
+2.33%
Becton, Dickinson and Co. (BDX) is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products across four business units: Medical Essentials, Connected Care, Biopharma Systems, and Interventional. As a diversified healthcare leader with over 72,000 employees and more than 60% of revenue from the United States, BDX holds a strong competitive position in the medical instruments and supplies industry, particularly in areas like infusion pumps, prefillable syringes, and infection prevention. The current investor narrative centers on the company's recent Q2 earnings beat and raised full-year profit outlook, which has driven a sharp stock rally, yet skepticism from some analysts persists regarding the sustainability of growth amid a challenging macro environment and recent revenue decline.…
BDX
Becton Dickinson
$192.00
Related headlines
Investment Opinion: Should I buy BDX Today?
We rate BDX as a Buy, supported by a consensus 'buy' recommendation and an average analyst target of $194.42, implying 1.3% upside from the current price. The thesis is that BDX's raised profit outlook and forward PE of 14.4x offer an attractive entry point for a defensive healthcare leader.
Sign up to view all
BDX 12-Month Price Forecast
The AI assessment is neutral with medium confidence. BDX's valuation is attractive on a forward basis, but the recent revenue decline and negative EPS introduce uncertainty. The stock's low beta makes it a defensive choice, but the lack of clear growth catalysts limits upside. Upgrades would require evidence of revenue stabilization and margin expansion, while downgrades would follow further deterioration in fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Becton Dickinson's 12-month outlook, with a consensus price target around $194.42 and implied upside of +1.3% versus the current price.
Average Target
$194.42
0 analysts
Implied Upside
+1.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$170 - $225
Analyst target range
The target price range spans from a low of $170.00 to a high of $225.00, with the average at $194.42. The high target of $225.00 implies a 17.2% upside from the current price, suggesting that some analysts see significant potential for growth, possibly driven by the company's raised profit outlook and new CFO appointment. The low target of $170.00 implies a downside of 11.5%, indicating that some analysts are concerned about the recent revenue decline and potential margin pressures. The spread between the low and high targets is $55.00, which is relatively wide, indicating high uncertainty about the company's future performance. Recent institutional ratings show a mix of actions, with no major upgrades or downgrades in the past few months, but the overall consensus remains positive, with a 'buy' recommendation.
Drowning in data?
Find the real signal!
Bulls vs Bears: BDX Investment Factors
BDX presents a mixed picture: strong operational improvements and a raised outlook support the bull case, but the recent revenue decline and negative EPS are significant bearish factors. Currently, the bull case has stronger evidence given the stock's momentum and forward valuation, but the key tension is whether the revenue decline is temporary or structural. If revenue growth resumes, the stock could re-rate higher; if not, the current rally may fade.
Bullish
- Raised FY2026 profit outlook: BDX raised its full-year profit outlook after a Q2 beat, signaling operational strength and cost discipline. This drove a sharp stock rally, with the stock up 25.4% in the past month, reflecting improved investor confidence.
- Strong forward valuation: The forward PE of 14.4x is significantly lower than the trailing PE of 25.2x, implying the market expects substantial earnings growth. This gap suggests the stock is attractively priced relative to future earnings potential.
- Low beta defensive profile: With a beta of 0.258, BDX offers stability in volatile markets, making it a defensive healthcare play. This is attractive for risk-averse investors seeking steady returns.
- Analyst consensus buy: The average analyst target of $194.42 is slightly above the current price of $192.00, with a high target of $225.00 implying 17.2% upside. The consensus recommendation is 'buy', reflecting positive sentiment.
Bearish
- Revenue decline in Q2: Q2 FY2026 revenue fell 10.6% YoY to $4.714 billion, from $5.272 billion a year ago. This marks a concerning top-line contraction, which could signal weakening demand or market share loss.
- Negative EPS in Q2: The company reported a net loss of $311 million and EPS of -$1.11 in Q2 FY2026, a sharp reversal from profitability in prior quarters. This raises questions about earnings quality and sustainability.
- High payout ratio: The dividend payout ratio is 71.3%, which is high and may limit future dividend growth or force cuts if earnings decline. This could deter income-focused investors.
- Wide analyst target range: The spread between the low target of $170.00 and high target of $225.00 is $55.00, indicating high uncertainty. The low target implies 11.5% downside, reflecting bearish concerns.
BDX Technical Analysis
BDX is currently in a strong recovery phase, with the stock price at $192.00 as of August 21, 2026, near its 52-week high of $192.30. The 1-year price change is -2.35%, indicating that despite the recent surge, the stock has only recovered to roughly its level from a year ago. The current price sits at 99.8% of the 52-week range (calculated as (192.00 - 127.59) / (192.30 - 127.59) = 99.8%), placing it at the upper end of the range, which suggests strong momentum but also potential overextension. The stock's beta of 0.258 indicates significantly lower volatility than the market, making it a defensive play, but the recent price action shows a sharp acceleration that may not be sustainable in the short term.
Beta
0.26
0.26x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$128-$192
Price range past year
Annual Return
-2.4%
Cumulative gain past year
| Period | BDX Return | S&P 500 |
|---|---|---|
| 1m | +25.4% | +3.6% |
| 3m | +30.1% | +2.7% |
| 6m | +3.6% | +11.4% |
| 1y | -2.4% | +18.7% |
| ytd | -1.5% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BDX Fundamental Analysis
BDX's revenue trajectory has been mixed, with the most recent quarter (Q2 FY2026, ending March 31, 2026) reporting revenue of $4.714 billion, a decline of 10.6% year-over-year (from $5.272 billion in Q2 FY2025). This follows a pattern of fluctuating quarterly revenues: Q1 FY2026 was $5.252 billion, Q4 FY2025 was $5.890 billion, Q3 FY2025 was $5.509 billion, and Q2 FY2025 was $5.272 billion. The revenue decline in the latest quarter is concerning, but the company raised its full-year profit outlook, suggesting that cost management and operational efficiency are offsetting top-line weakness. The revenue segments show a balanced mix, with Medical at $2.4 billion and Life Sciences at $2.5 billion, indicating that both segments are roughly equal contributors, though the decline appears broad-based.
Quarterly Revenue
$4.7B
2026-03
Revenue YoY Growth
-10.6%
YoY Comparison
Gross Margin
45.7%
Latest Quarter
Free Cash Flow
$3.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BDX Overvalued?
Given that BDX's trailing twelve-month net income is positive (as evidenced by a positive EPS of $0.04 in the key metrics), the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 25.2x, while the forward PE is 14.4x, implying that the market expects significant earnings growth in the coming year. This gap between trailing and forward PE suggests that the market is pricing in a strong recovery in profitability, which is consistent with the company's raised profit outlook. The PS ratio is 1.93x, which is relatively low for a medical technology company, but the PE ratio is more appropriate given the positive earnings.
PE
25.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~55x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt-to-equity ratio of 0.755, indicating significant leverage, and a negative EPS in Q2 FY2026, which could strain cash flows. The payout ratio of 71.3% leaves little room for dividend increases if earnings deteriorate. Additionally, the company's reliance on continued cost management to offset revenue declines poses a risk if cost savings are exhausted.
FAQ
Key risks include: 1) Financial: high debt-to-equity of 0.755 and negative EPS in Q2, which could strain cash flows. 2) Competitive: potential market share losses in core segments. 3) Macro: sensitivity to healthcare spending and regulatory changes. 4) Company-specific: reliance on cost management to offset revenue declines. The most severe risk is a prolonged revenue decline, which could lead to further earnings deterioration.
The 12-month forecast is mixed: the bull case (30% probability) targets $210-$225, the base case (50%) targets $190-$200, and the bear case (20%) targets $160-$170. The base case is most likely, aligning with the average analyst target of $194.42. The key assumption is that revenue stabilizes and margins hold, which would support the current valuation.
BDX appears undervalued on a forward basis, with a forward PE of 14.4x versus the trailing PE of 25.2x, indicating expected earnings growth. The PS ratio of 1.93x is also modest for a medical technology company. However, the negative EPS in Q2 raises concerns, and the stock trades near its 52-week high, so it's not a bargain. Overall, the valuation is fair given the mixed fundamentals.
BDX is a good buy for investors seeking a defensive healthcare stock with a reasonable valuation. The forward PE of 14.4x is attractive, and the analyst consensus is 'buy' with an average target of $194.42, implying slight upside. However, the recent revenue decline and negative EPS are risks, so it's best for those with a medium-to-long-term horizon who can tolerate short-term volatility.
BDX is better suited for long-term investment due to its defensive nature and low beta of 0.258. The stock offers a dividend yield of 2.84%, providing income, and its valuation is reasonable on a forward basis. Short-term trading is possible given recent momentum, but the stock's volatility is low, limiting quick gains. A minimum holding period of 3-5 years is recommended to ride out cyclical fluctuations.
